NCT06045806 2026-03-05
KarMMa-9
Celgene
Phase 3 Active not recruiting
Clinical Trials
10 trialsNCT03601078 2026-03-04
KarMMa-2
Celgene
Phase 2 Completed
NCT06357754 2026-01-22
Transgene Assay Testing Service of Tumor Samples From Patients Who Received a Bristol-Myers Squibb Manufactured Gene Modified Cell Therapy and Have a Qualifying Second Primary Malignancy
Bristol-Myers Squibb
Recruiting
NCT04771078 2025-12-12
Expanded Access Protocol (EAP) for Participants Receiving Idecabtagene Vicleucel That is Nonconforming for Commercial Release
Celgene
Available
NCT03361748 2025-05-23
KarMMa
Celgene
Phase 2 Completed
NCT06698887 2024-12-13
A Study to Evaluate the Long-Term Safety of Idecabtagene Vicleucel Treatment in Adults With Newly Diagnosed Multiple Myeloma in Korea
Bristol-Myers Squibb
Recruiting
NCT06154902 2023-12-04
ABE-DESCART
Bristol-Myers Squibb
Active not recruiting
NCT04196491 2023-08-23
KarMMa-4
Celgene
Phase 1 Completed
NCT02658929 2023-01-23
Study of bb2121 in Multiple Myeloma
Celgene
Phase 1 Completed
NCT03651128 2022-12-15
KarMMa-3
Celgene
Phase 3 Active not recruiting